HomepageALMKT • EPA
add
Mauna Kea Technologies SA
Vorige slotkoers
€ 0,12
Dag-range
€ 0,11 - € 0,12
Jaar-range
€ 0,061 - € 0,53
Beurswaarde
7,32Â mln. EUR
Gem. volume
1,25Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
EPA
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 2,07Â mln. | 6,69% |
Bedrijfskosten | 3,13Â mln. | -12,81% |
Netto inkomsten | -2,86Â mln. | 12,38% |
Netto winstmarge | -137,92 | 17,88% |
Winst per aandeel | — | — |
EBITDA | -974,50K | 52,10% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 2,02Â mln. | -74,80% |
Totale activa | 16,24Â mln. | -29,18% |
Totale passiva | 40,63Â mln. | 1,04% |
Totaal aandelenvermogen | -24,39 mln. | — |
Uitstaande aandelen | 69,92 mln. | — |
Koers-boekwaardeverhouding | -0,32 | — |
Rendement op activa | -18,11% | — |
Rendement op kapitaal | -39,01% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -2,86Â mln. | 12,38% |
Operationele kasstroom | -1,26Â mln. | 30,14% |
Kasstroom uit beleggingen | -111,00K | 16,85% |
Kasstroom uit financiering | 468,00K | -83,22% |
Nettomutatie in liquide middelen | -890,50K | -205,07% |
Vrije kasstroom | -73,50K | 93,34% |
Over
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Opgericht
2000
Website
Werknemers
65